| Active substance | Pembrolizumab |
| Holder | MSD Belgium |
| Status | Running |
| Indication | in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) for the treatment of locally advanced FIGO 2014 stage III-IVA cervical cancer, in adults who have not received prior definitive therapy. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 13/09/2024 |